{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:14:46Z","timestamp":1778087686610,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["U114000"],"award-info":[{"award-number":["U114000"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["UBH12097"],"award-info":[{"award-number":["UBH12097"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7244388"],"award-info":[{"award-number":["7244388"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2705803"],"award-info":[{"award-number":["2023YFC2705803"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471767"],"award-info":[{"award-number":["82471767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.humpath.2026.106102","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:31:14Z","timestamp":1773041474000},"page":"106102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expression characteristics of clinically relevant antibody\u2013drug conjugate targets in gestational trophoblastic neoplasia"],"prefix":"10.1016","volume":"172","author":[{"given":"Xiaoyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingci","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-1021","authenticated-orcid":false,"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.humpath.2026.106102_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijgo.70275","article-title":"Diagnosis and management of gestational trophoblastic disease: 2025 update","volume":"171","author":"Ngan","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.humpath.2026.106102_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101974","article-title":"Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study","volume":"59","author":"Wang","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.humpath.2026.106102_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.humpath.2026.106102_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106102_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/PGP.0000000000001119","article-title":"Antibody-drug conjugate biomarker expression in gestational trophoblastic disease: folate receptor alpha, Nectin-4, Trop-2, and tissue factor","volume":"45","author":"Lin","year":"2026","journal-title":"Int J Gynecol Pathol"},{"issue":"13","key":"10.1016\/j.humpath.2026.106102_bib6","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106102_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2017.04.010","article-title":"Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: a retrospective cohort study","volume":"146","author":"Kong","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2026.106102_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1610918","article-title":"Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia","volume":"29","author":"Cheng","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"10.1016\/j.humpath.2026.106102_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/his.13882","article-title":"PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia","volume":"75","author":"Zong","year":"2019","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.humpath.2026.106102_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.32074\/1591-951X-937","article-title":"TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma","volume":"116","author":"Brunelli","year":"2024","journal-title":"Pathologica"},{"issue":"3","key":"10.1016\/j.humpath.2026.106102_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/CBM-230230","article-title":"Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma","volume":"39","author":"Attia","year":"2024","journal-title":"Cancer Biomarkers"},{"issue":"7","key":"10.1016\/j.humpath.2026.106102_bib12","first-page":"1391","article-title":"Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development","volume":"128","author":"Moretto","year":"2023","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2026.106102_bib13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/jog.13593","article-title":"Laparoscopic diagnosis and treatment of an isolated epithelioid trophoblastic tumor in recto-uterine pouch","volume":"44","author":"Jiang","year":"2018","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"10.1016\/j.humpath.2026.106102_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-nectin 4: a promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol Cancer Therapeut"},{"issue":"2","key":"10.1016\/j.humpath.2026.106102_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.humpath.2026.106102_bib16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2147\/OTT.S370900","article-title":"Targeted treatment of locally advanced and metastatic urothelial cancer: Enfortumab vedotin in context","volume":"15","author":"Hoffman-Censits","year":"2022","journal-title":"OncoTargets Ther"},{"issue":"6","key":"10.1016\/j.humpath.2026.106102_bib17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106102_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","article-title":"Emerging roles for folate receptor FOLR1 in signaling and cancer","volume":"33","author":"Nawaz","year":"2022","journal-title":"Trends Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.humpath.2026.106102_bib19","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3802\/jgo.2025.36.e74","article-title":"FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma","volume":"36","author":"Leung","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.humpath.2026.106102_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.humpath.2026.106102_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"3-4","key":"10.1016\/j.humpath.2026.106102_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"issue":"16","key":"10.1016\/j.humpath.2026.106102_bib23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"10411","key":"10.1016\/j.humpath.2026.106102_bib24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.humpath.2026.106102_bib25","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.humpath.2026.106102_bib26","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical activity of SAR408701: a novel Anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.humpath.2026.106102_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cells12212517","article-title":"HER3: toward the prognostic significance, therapeutic potential, current challenges, and future therapeutics in different types of cancer","volume":"12","author":"Majumder","year":"2023","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.humpath.2026.106102_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413416","article-title":"CLDN6: from traditional barrier function to emerging roles in cancers","volume":"22","author":"Qu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.humpath.2026.106102_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.humpath.2026.106102_bib30","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.humpath.2026.106102_bib31","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:53:53Z","timestamp":1778086433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"alternative-id":["S0046817726000717"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106102","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression characteristics of clinically relevant antibody\u2013drug conjugate targets in gestational trophoblastic neoplasia","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106102"}}